In a recent study published in the Proceedings of the National Academy of Sciences, researchers assessed the impact of an anti-CD3 monoclonal antibody (mAb) called Foralumab in coronavirus disease ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
Tiziana Life Sciences Ltd. (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a ...
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ...
Treatment with anti-CD19 bispecific T-cell engager and CAR T therapies can lead to T-cell exhaustion and treatment failure. Novartis AG’s first-in-class anti-CD19, anti-CD3 and anti-CD2 IgG-like ...
The randomized, double-blind, placebo-controlled Phase 2a trial, known as INFORM-MS (NCT06292923), enrolled a total of 48 patients across three cohorts at multiple leading U.S. clinical sites. The ...
Janssen Pharmaceutica NV reported on the company’s novel fully human immunoglobulin G1 CD79bxCD20xCD3 trispecific antibody JNJ-80948543, comprising an anti-CD3 ε single-chain variable fragment (scFv), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results